GlaxoSmithKline ‘to publish malaria research information’

GlaxoSmithKline, a manufacturer of pharmacy products, has revealed that it will open up its database containing thousands of potential anti-malaria compounds.

The information, which has remained confidential until now, will be shared with the world’s scientists as they work to develop a cure for the mosquito-transmitted condition.

In addition to the data on 13,500 molecules, the organisation stated that it will also establish a not-for-profit foundation in Europe with a starting investment of $8 million (4.91 million pounds).

This, it added, will work towards funding research and establishing greater knowledge-sharing between scientists.

“GSK has the capability to make a difference and a genuine appetite to change the landscape of healthcare for the world’s poorest people,” stated chief executive of the organisation Andrew Witty.

According to the World Health Organization, malaria is caused by plasmodium which are transmitted via mosquitoes and multiply in the liver, before attacking the red blood cells of those infected.